Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Sanford Cancer Center at Sanford USD Medical Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Baptist Regional Cancer Center at Baptist Hospital of East Tennessee
mi
from
Knoxville, TN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Baptist Regional Cancer Center at Baptist Hospital of East Tennessee
mi
from
Knoxville, TN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
UT Southwestern University Hospital - Zale Lipshy
mi
from
Dallas, TX
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
UT Southwestern University Hospital - Zale Lipshy
mi
from
Dallas, TX
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
West Virginia University Robert C. Byrd Health Sciences Center, Charleston Division
mi
from
Charleston, WV
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
West Virginia University Robert C. Byrd Health Sciences Center, Charleston Division
mi
from
Charleston, WV
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Fox Valley Hematology and Oncology - East Grant Street
mi
from
Appleton, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Fox Valley Hematology and Oncology - East Grant Street
mi
from
Appleton, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Green Bay Oncology, Limited at St. Mary's Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Mary's Hospital Medical Center - Green Bay
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Dean Medical Center - Madison
mi
from
Madison, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Dean Medical Center - Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Holy Family Memorial Medical Center Cancer Care Center
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated:  11/25/2015
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens
Status: Enrolling
Updated: 11/25/2015
Marshfield Clinic - Marshfield Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Status: Enrolling
Updated:  11/27/2015
Shapiro, Stafford and Yee
mi
from
Arcadia, CA
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Status: Enrolling
Updated: 11/27/2015
Shapiro, Stafford and Yee
mi
from
Arcadia, CA
Click here to add this to my saved trials
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Status: Enrolling
Updated:  11/27/2015
Clintell, Inc.
mi
from
Skokie, IL
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Status: Enrolling
Updated: 11/27/2015
Clintell, Inc.
mi
from
Skokie, IL
Click here to add this to my saved trials
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Status: Enrolling
Updated:  11/27/2015
CER - Instituto Medico
mi
from
Buenos Aires,
PF-00299804 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Standard Therapy for Advanced or Metastatic Cancer
A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
Status: Enrolling
Updated: 11/27/2015
CER - Instituto Medico
mi
from
Buenos Aires,
Click here to add this to my saved trials
Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)
Dynamic MRI for Lung Tumor Motion and Lung Function
Status: Enrolling
Updated:  11/30/2015
Ummc Msgcc
mi
from
Baltimore, MD
Dynamic Magnetic Resonance Imaging (MRI) for Lung Tumor Motion and Lung Function (GCC 0943)
Dynamic MRI for Lung Tumor Motion and Lung Function
Status: Enrolling
Updated: 11/30/2015
Ummc Msgcc
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Billings Clinic
mi
from
Billings, MT
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated:  11/30/2015
Ottawa Health Research Institute
mi
from
Ottawa,
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
A Phase I Dose Escalation Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intravenous Infusion in Patients With Refractory Solid Tumors
Status: Enrolling
Updated: 11/30/2015
Ottawa Health Research Institute
mi
from
Ottawa,
Click here to add this to my saved trials
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors
Status: Enrolling
Updated:  12/1/2015
The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute
mi
from
Columbus, OH
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors
Status: Enrolling
Updated: 12/1/2015
The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute
mi
from
Columbus, OH
Click here to add this to my saved trials
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors
Status: Enrolling
Updated:  12/1/2015
Georgetown University Medical Center
mi
from
Washington,
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors
Status: Enrolling
Updated: 12/1/2015
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated:  12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients
Status: Enrolling
Updated: 12/2/2015
Arizona Cancer Center at University of Arizona Health Sciences Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/2/2015
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/2/2015
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/2/2015
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer
L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/2/2015
University of Pennsylvania Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated:  12/8/2015
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
Status: Enrolling
Updated: 12/8/2015
Western Regional Medical Center, Inc
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Pinnacle Oncology
mi
from
Scottsdale, AZ
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Pinnacle Oncology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated:  12/9/2015
Northwestern University
mi
from
Chicago, IL
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Phase 1b/2, Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors, Multiple Myeloma or Lymphoma
Status: Enrolling
Updated: 12/9/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/10/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/10/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen
Status: Enrolling
Updated:  12/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen
Status: Enrolling
Updated: 12/10/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen
Status: Enrolling
Updated:  12/10/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen
Status: Enrolling
Updated: 12/10/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen
Status: Enrolling
Updated:  12/10/2015
Froedtert Memorial Lutheran Hospital
mi
from
Miwaukee, WI
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice
Pilot Study of Model Based Iterative Reconstruction Using 64-Slice Multidetector-Row CT Datasets Obtained From the Central Nervous System, Thorax, and Abdomen
Status: Enrolling
Updated: 12/10/2015
Froedtert Memorial Lutheran Hospital
mi
from
Miwaukee, WI
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
mi
from
Baltimore, MD
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Case Western Reserve Univ
mi
from
Cleveland, OH
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  12/10/2015
Billings Clinic Cancer Center
mi
from
Billings, MT
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Randomized Phase II Study of Single Agent OSI-906, an Oral, Small Molecule, Tyrosine Kinase Inhibitor (TKI) of the Insulin Growth Factor-1 Receptor (IGF-1R) Versus Topotecan for the Treatment of Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 12/10/2015
Billings Clinic Cancer Center
mi
from
Billings, MT
Click here to add this to my saved trials